Skip Navigation LinksHome > July 2014 - Volume 29 - Issue 4 > Long-acting paliperidone palmitate – interim results of an o...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000028
Original Articles

Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization

Taylor, Davida,b; Olofinjana, Olubankea

Collapse Box

Abstract

Paliperidone palmitate (PP) is a recently introduced long-acting atypical, or second-generation, antipsychotic. Published data on PP are currently limited to controlled trials and case reports. In this observational study, we followed up 200 consecutive patients prescribed PP in normal practice. After 1 year, 65% of patients were still receiving PP. The number of admissions to hospital in the year following PP initiation was 0.49/patient compared with 0.69/patient/year, 3 years before initiation (P=0.0001). The mean number of bed days fell from 38.78 to 23.09/patient/year over the corresponding period (P=0.0001). The median number of bed days 3 years before PP initiation was 21.50/year and in the year following PP initiation, it was 0. Outcomes were numerically but not statistically better in those continuing PP than in those who ceased PP within a year of initiation. PP was effective and well-tolerated and, given its positive effect on hospital bed days, broadly cost-effective.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.